Myoridge Co. Ltd.

http://myoridge.co.jp
Email ▶ makita@myoridge.co.jp

Products

Drug trials using cardiomyocytes derived from iPS cells are increasingly gaining attention, especially the research in the field of safety evaluation is progressing globally. Among those, the inspection of the cardiac effects is the most important issue of new drug discovery. As a result, the demand for cardiomyocytes derived from iPS cells is expected to increase in the future.

We produce cardiomyocytes derived from iPS cells using a method developed from "the protein-free method of inducing differentiation", patented by Kyoto University and succeeded in the large-scale and low-cost production of mature cardiomyocytes.

Its largest feature is the high level of cell maturity, such as the muscle development and gene expression that is close to an adult's. This feature means a good drug response. With the introduction of this cardiomyocyte, the efficiency of the inspection of drug's side effects and new drug discovery will be significantly improved.

Message

Through the development of cardiomyocytes, we hope to contribute to new drug discovery and regenerative medicine. This is a technique that has potential application in a wide range of fields where the research involves the cardiomyocytes. We believe that this technique is compatible in many fields. Please feel free to contact us for any inquiries.

Reference information

- Patent 1: "the compound promoting myocardial differentiation of pluripotent stem cells" WO 2015037706 A1
- Patent 2: "method for inducing myocardial differentiation of pluripotent stem cells using low molecule compounds" WO 2015182765 A1
- Patent 3: "Myocardial differentiation promoting agent of pluripotent stem cells containing EGF receptor inhibitor" WO 2014136519 A1
- Patent 4: "Myocardial differentiation induction of pluripotent stem cells" WO 2013111875 A1
- Patent 5: "myocardial differentiation promoting agent of pluripotent stem cells" WO 2012026491 A1 approved in the United States
- Patent 6: "freezing and thawing method of cardiomyocytes" application filed

*License Agreements of all patents are signed between Myoridge Co. Ltd and Kyoto University. Myoridge receives the exclusive license of patent 6.
Joint-research with Shinshu University is being conducted.